OBSTETRICAL AND NEONATAL OUTCOMES AMONG PREGNANCIES COMPLICATED BY HYPERPARATHYROIDISM: SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/nvh5mt79Keywords:
Hyperparathyroidsm, pregnancy, obstetric, neonatalAbstract
Background: Primary hyperparathyroidism (PHPT) is a relatively common disorder of the parathyroid glands, causing skeletal, renal, and cardiac complications. As etiological features of PHPT, single adenoma, hyperplasia, carcinoma, and familiar causes (MEN multiple endocrine neoplasia, FHH familiar hypocalciuric hypercalcemia, hyperparathyroidismjaw tumor syndrome) are presented. Primary hyperparathyroidism in pregnancy has an incidence of 1, which is underestimated due to the plethora of undiagnosed cases.
The aim: This study aims to show about obstetrical and neonatal outcomes among pregnancies complicated by hyperparathyroidism.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 10 articles, whereas the results of our search on SagePub brought up 60 articles. The results of the search conducted for the last year of 2013 yielded a total 2 articles for PubMed and 14 articles for SagePub. The result from title screening, a total 1 articles for PubMed and 10 articles for SagePub. In the end, we compiled a total of 7 papers. We included five research that met the criteria.
Conclusion: Pregnancy complicated by PHPT may lead to serious maternal and infant complications. MDT consultation ensures timely diagnosis, comprehensive treatment for the patients and better pregnancy outcomes.
References
Malekar-Raikar S, Sinnott BP. Primary Hyperparathyroidism in Pregnancy—A Rare Cause of Life-Threatening Hypercalcemia: Case Report and Literature Review. Case Rep Endocrinol. 2011;2011:1–6.
Kattar N, Migneron M, Debakey MS, Haidari M, Pou AM, McCoul ED. Advanced Computed Tomographic Localization Techniques for Primary Hyperparathyroidism: A Systematic Review and Meta-analysis. JAMA Otolaryngol - Head Neck Surg. 2022;148(5):448–56.
Ali DS, Dandurand K, Khan AA. Primary hyperparathyroidism in pregnancy: Literature review of the diagnosis and management. J Clin Med. 2021;10(13).
Arshad MF, Arambewela MH, Bennet WM, Sterrenburg M, Balasubramanian SP. Primary hyperparathyroidism in pregnancy: experience of a tertiary centre. Surg Today [Internet]. 2023;53(4):470–5. Available from: https://doi.org/10.1007/s00595-022-02583-8
Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, Chang Y, et al. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Bone Miner Res. 2022;37(11):2351–72.
Trahan MJ, Antinora C, Czuzoj-Shulman N, Benjamin A, Abenhaim HA. Obstetrical and neonatal outcomes among pregnancies complicated by hyperparathyroidism. J Matern Neonatal Med [Internet]. 2023;36(1). Available from: https://doi.org/10.1080/14767058.2023.2170748
Cassir G, Sermer C, Malinowski AK. Impact of Perinatal Primary Hyperparathyroidism on Maternal and Fetal and Neonatal Outcomes: Retrospective Case Series. J Obstet Gynaecol Canada [Internet]. 2020 Jun;42(6):750–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1701216320300487
Rigg J, Gilbertson E, Barrett HL, Britten FL, Lust K. Primary Hyperparathyroidism in Pregnancy: Maternofetal Outcomes at a Quaternary Referral Obstetric Hospital, 2000 Through 2015. J Clin Endocrinol Metab. 2018;104(3):721–9.
Jiao H ning, Sun L hao, Liu Y, Zhou J qiao, Chen X, Liu J min, et al. Multidisciplinary team efforts to improve the pregnancy outcome of pregnancy complicated with primary hyperparathyroidism: case series from a single hospital. BMC Pregnancy Childbirth. 2021;21(1):1–9.
Hirsch D, Kopel V, Nadler V, Levy S, Toledano Y, Tsvetov G. Pregnancy outcomes in women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(5):2115–22.
Islam AK. Advances in the diagnosis and the management of primary hyperparathyroidism. Ther Adv Chronic Dis. 2021;12:1–20.
Kiely M, Hemmingway A, O’Callaghan KM. Vitamin D in pregnancy: current perspectives and future directions. Ther Adv Musculoskelet Dis. 2017;9(6):145–54.
Waterhouse M, Sanguineti E, Baxter C, Duarte Romero B, McLeod DSA, English DR, et al. Vitamin D supplementation and risk of falling: outcomes from the randomized, placebo-controlled D-Health Trial. J Cachexia Sarcopenia Muscle. 2021;12(6):1428–39.
McCarthy A, Howarth S, Khoo S, Hale J, Oddy S, Halsall D, et al. Management of primary hyperparathyroidism in pregnancy: A case series. Endocrinol Diabetes Metab Case Reports. 2019;2019(1).
Pliakos I, Chorti A, Moysidis M, Kotsovolis G, Kaltsas T, Pana A, et al. Parathyroid adenoma in pregnancy: A case report and systematic review of the literature. Front Endocrinol (Lausanne). 2022;13(October):1–12.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
